Tempest Therapeutics Inc (TPST) USD0.001
Sell:$6.12Buy:$6.37
$0.05
(0.80%)
- This stock can be held in a
Stocks and Shares ISA$0.05
(0.80%)$0.05
(0.80%)Company Information
About this company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Key people
Key facts
- EPICTPST
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS87978U2078
- Market cap$22.94m
- Employees24
- Shares in issue3.68m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.